Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Truxima Rituximab Cancelled
Atriance Nelarabine Cancelled
TBD Rituximab Cancelled
TBD Bevacizumab Cancelled
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
Xolair Omalizumab Asthma, severe persistent Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Twynsta Telmisartan / Amlodipine Hypertension Cancelled